160231-69-6Relevant articles and documents
Preclinical Pharmacology and Pharmacokinetics of GW433908, a Water-Soluble Prodrug of the Human Immunodeficiency Virus Protease Inhibitor Amprenavir
Furfine, Eric S.,Baker, Christopher T.,Hale, Michael R.,Reynolds, David J.,Salisbury, Jo A.,Searle, Andy D.,Studenberg, Scott D.,Todd, Dan,Tung, Roger D.,Spaltenstein, Andrew
, p. 791 - 798 (2004)
GW433908 is the water-soluble, phosphate ester prodrug of the human immunodeficiency virus type 1 protease inhibitor amprenavir (APV). A high-yield synthesis of GW433908 is achieved by phosphorylation of the penultimate precursor of APV with phosphorous o
PROCESS FOR PREPARATION OF SUBSTANTIALLY PURE FOSAMPRENAVIR CALCIUM AND ITS INTERMEDIATES
-
Paragraph 0051, (2013/07/19)
The present invention relates to fosamprenavir calcium (Ia) substantially free of isomer impurity, (3R) tetrahydro -3 -furanyl(1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-(phosphonooxy)propyl carbamate (Ib), and its process for preparat
PROCESS FOR PREPARATION OF SUBSTANTIALLY PURE FOSAMPRENAVIR CALCIUM AND ITS INTERMEDIATES
-
Page/Page column 14, (2012/03/27)
The present invention relates to fosamprenavir calcium (la) substantially free of isomer impurity, (3R) tetrahydro-3-furanyl(1S,2R)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino]- 1-benzyl-2-(phosphonooxy)propyl carbamate (lb), and its process for prepar